Shots:
- The EC has approved Xoanacyl (ferric citrate complex) for chronic kidney disease; UK’s MAA was filed via MHRA’s IRP
- Approval was supported by 3 pivotal trials conducted by Akebia Therapeutics, which showed increased iron levels along with reduction in serum phosphorus in CKD pts
- Averoa licensed Xoanacyl from Akebia in Dec 2022, enhancing its dossier with a re-engineered clinical package to support dual indications for EU pts. Averoa is currently seeking commercial partners for EU launch & distribution
Ref: Globenewswire | Image: Averoa | Press Release
Related News:- Averoa Receives the CHMP’s Positive Opinion for Xoanacyl to Treat Chronic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
